Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 6/20 | 0.67 |
| ▸ | CDK2 | P24941 | 6/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.67 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25278128 | 0.88 | MEN1 (0.80) | CCNA2CDK2CDK5CDK5R1MEN1 | |
| SCHEMBL25222239 | 0.87 | CCNA2 (0.87) | CCNA2CDK2CDK5CDK5R1MEN1 | |
| SCHEMBL5744164 | 0.83 | CDK4 (0.74) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL5743097 | 0.83 | CDK4 (0.68) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL25609561 | 0.83 | CCNA2 (0.67) | CCNA2CDK2CDK5CDK5R1MEN1 | |
| SCHEMBL20142146 | 0.83 | CCNA2 (0.90) | CCNA2CDK2CDK5CDK5R1MEN1 | |
| SCHEMBL4478062 | 0.83 | CCNA2 (0.87) | CCNA2CDK2CDK5CDK5R1MEN1 | |
| SCHEMBL5743411 | 0.82 | CDK4 (0.87) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL13633841 | 0.82 | CCNA2 (0.88) | CCNA2CDK2CDK5CDK5R1MEN1 | |
| SCHEMBL4487774 | 0.81 | CDK5 (0.68) | CCNA2CDK2CDK5CDK5R1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | CCNA2 851/4885CDK2 239/4885CDK5 591/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | CCNA2 851/4885CDK2 239/4885CDK5 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.